The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2008

Filed:

Jun. 08, 2004
Applicants:

Philippe Crine, Outremont, CA;

Guy Boileau, Brossard, CA;

Inventors:

Philippe Crine, Outremont, CA;

Guy Boileau, Brossard, CA;

Assignee:

Universite De Montreal, Montreal, Quebec, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/48 (2006.01); C12N 11/00 (2006.01); C12N 9/14 (2006.01); C07K 14/00 (2006.01); C12Q 1/34 (2006.01); C12Q 1/37 (2006.01); C12N 15/00 (2006.01); C12N 5/10 (2006.01); C12P 21/00 (2006.01); C07H 21/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

This invention relates to a soluble form of PHEX, PHEX being a type II integral membrane glycoprotein. This enzyme is the gene product of a phosphate-regulating gene with homologies to endopeptidases on the X chromosome. To produce a soluble form of PHEX, the transmembrane anchor domain has been modified to encode a signal peptidase coding sequence. The soluble PHEX therefore comprises the active ectodomain. An inactive mutant of PHEX is also an object of this invention. Both soluble and inactive mutant forms of PHEX can be used to screen ligands to PHEX. These ligands can also be used as substrates or inhibitors of PHEX. PHEX being phosphaturic, an inhibitor thereof will be used to treat phosphaturia and/or hypophosphatemia. On the opposite, a substrate for PHEX or PHEX itself can be used to treat hyperphosphatemia.


Find Patent Forward Citations

Loading…